Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology.
"This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. "Calendar age is less important than other measures, such as whether a patient is physically fit enough to get through a transplant, has a lot of comorbidities, and what his or her performance status is."
MDS comprises several types of bone marrow failure causing severe anemia.
Abel, senior author Edwin P. Alyea, MD, and their colleagues analyzed the Dana-Farber experience over 10 years with reduced-intensity conditioning "mini-transplants" in patients with MDS, a group of bone-marrow disorders that generally develop in older adults. The mean age at diagnosis is 71.
Transplantation is the only potentially curative treatment for MDS in any age group, but many patients are not healthy enough to undergo the procedure.
The Dana-Farber researchers studied the records of 67 patients ranging in age from 60 to 74. The majority - 64 percent - received transplants from unrelated donors. Comparing recipients who were 60 to 65 with those older than 66, there were no statistically significant differences in overall survival at four years or in four-year survival without disease progression.
Patients in the two age groups also had comparable rates of deaths that weren't caused by disease relapse, and in the cumulative incidence of relapse itself. In addition, using significant components of the revised International Prognostic Scoring System (IPSS-R), the authors created a new risk score to predict four-year overall survival at time of transplantation. In two multivariable models, one that included the IPSS-R and another that included the new score, age was not a significant predictor of overall survival.
The study findings, said Abel, "are good news, since patients with MDS tend to be elderly and this is the only curative treatment at the moment for this disease."
"We hope this contributes to a growing body of evidence that treatment options should not be denied because of advanced age alone," said Alyea. "This is especially important in the older patients who have Medicare."
Dr. Abel's work was in part supported by a Scholar in Clinical Research Award from the Leukemia and Lymphoma Society.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Blood / Hematology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Institute, Dana-Farber Cancer. "Access to transplants for MDS should not be limited by age." Medical News Today. MediLexicon, Intl., 10 Dec. 2013. Web.
16 Apr. 2014. <http://www.medicalnewstoday.com/releases/269870>
Institute, D. (2013, December 10). "Access to transplants for MDS should not be limited by age." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269870.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.